Skip to main content
NewslettersWatchlist

Nevro Corp(NVRO-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low9.76
Day High10.74
Open:10.59
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Why Nevro Stock Lagged the Market on Thursday
PR Newswire
Nevro to Report Third Quarter 2023 Financial Results
PR Newswire
New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy
PR Newswire
Nevro Announces Participation in Upcoming Investor Conferences
PR Newswire
New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy
Motley Fool
Why Shares of Nevro Are Down Wednesday
PR Newswire
Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance
PR Newswire
Nevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual Conference
PR Newswire
Nevro to Present at the Canaccord Genuity 43rd Annual Growth Conference
PR Newswire
Nevro to Report Second Quarter 2023 Financial Results
PR Newswire
Nevro Announces Painful Diabetic Neuropathy Clinical Data Presentations at the American Diabetes Association 83rd Scientific Sessions
PR Newswire
Nevro Names New Chief Commercial Officer
PR Newswire
Nevro to Present at Jefferies Healthcare Conference
PR Newswire
Nevro Corp. Announces New Employment Inducement Grant under Section 303A.08 of the NYSE Listed Company Manual
PR Newswire
Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance
PR Newswire
Nevro Announces Enrollment of First Patient in PDN Sensory Study
PR Newswire
Nevro Announces Participation in Upcoming Investor Conferences
Motley Fool
Why Nevro Stock Is Tanking Today
PR Newswire
Nevro Names Kevin Thornal as New Chief Executive Officer and President
PR Newswire
Nevro to Report First Quarter 2023 Financial Results
PR Newswire
Nevro Announces U.S. Full Market Launch of Revolutionary HFX iQ™ Spinal Cord Stimulation System to Personalize Treatment of Chronic Pain
PR Newswire
Nevro to Participate in Wells Fargo 2023 Medtech Innovation Spotlight Call Series
PR Newswire
Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides First Quarter and Complete Full-Year 2023 Guidance
PR Newswire
Nevro Named to 2023 Bloomberg Gender-Equality Index for Second Consecutive Year
PR Newswire
Nevro to Report Fourth Quarter and Full-Year 2022 Financial Results
PR Newswire
Nevro to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society (NANS) 26th Annual Meeting
PR Newswire
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance
PR Newswire
Nevro to Present at 41st Annual J.P. Morgan Healthcare Conference
PR Newswire
Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy
PR Newswire
Nevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain
PR Newswire
Nevro Comments on UnitedHealthcare Medical Coverage Policy Update
PR Newswire
Nevro to Report Third Quarter 2022 Financial Results

Profile

Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Additionally, the company's HF10 therapy provides long-lasting relief from chronic back and leg pain. Nevro's flagship Senza SCS system has been consistently driving the top line. Since its commercial launch in the United States, the system raked in significant revenues. These apart, Senza is commercially available in Europe since 2010 and in Australia since 2011.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.